Provention Bio Inc. [NASDAQ: PRVB] stock went on an upward path that rose over 5.84% on Thursday, amounting to a one-week price increase of more than 17.27%. The company report on June 11, 2021 that SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – PRVB.
Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. (“Provention” or the “Company”) (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased Provention securities during the Class Period, you have until July 20, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at firstname.lastname@example.org or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Over the last 12 months, PRVB stock dropped by -37.88%. The average equity rating for PRVB stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $513.61 million, with 62.26 million shares outstanding and 47.69 million shares in the current float. Compared to the average trading volume of 2.64M shares, PRVB stock reached a trading volume of 1554356 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Provention Bio Inc. [PRVB]:
SVB Leerink have made an estimate for Provention Bio Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 09, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $27 to $25. The new note on the price target was released on April 09, 2021, representing the official price target for Provention Bio Inc. stock. Previously, the target price had yet another raise from $20 to $26, while H.C. Wainwright kept a Buy rating on PRVB stock.
The Average True Range (ATR) for Provention Bio Inc. is set at 0.80 The Price to Book ratio for the last quarter was 2.76, with the Price to Cash per share for the same quarter was set at 3.29.
PRVB Stock Performance Analysis:
Provention Bio Inc. [PRVB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.27. With this latest performance, PRVB shares gained by 21.46% in over the last four-week period, additionally sinking by -49.16% over the last 6 months – not to mention a drop of -37.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRVB stock in for the last two-week period is set at 52.54, with the RSI for the last a single of trading hit 55.52, and the three-weeks RSI is set at 49.81 for Provention Bio Inc. [PRVB]. The present Moving Average for the last 50 days of trading for this stock 8.02, while it was recorded at 7.60 for the last single week of trading, and 12.73 for the last 200 days.
Insight into Provention Bio Inc. Fundamentals:
Return on Total Capital for PRVB is now -102.76, given the latest momentum, and Return on Invested Capital for the company is -101.66. Return on Equity for this stock declined to -102.03, with Return on Assets sitting at -91.91. When it comes to the capital structure of this company, Provention Bio Inc. [PRVB] has a Total Debt to Total Equity ratio set at 0.71. Additionally, PRVB Total Debt to Total Capital is recorded at 0.70, with Total Debt to Total Assets ending up at 0.61. Long-Term Debt to Equity for the company is recorded at 0.64, with the Long-Term Debt to Total Capital now at 0.64.
Provention Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.90 and a Current Ratio set at 7.90.
PRVB Stock EPS
With the latest financial reports released by the company, Provention Bio Inc. posted -0.45/share EPS, while the average EPS was predicted by analysts to be reported at -0.28/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -60.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRVB.
Provention Bio Inc. [PRVB] Insider Position Details
There are presently around $192 million, or 40.20% of PRVB stock, in the hands of institutional investors. The top three institutional holders of PRVB stocks are: BLACKROCK INC. with ownership of 4,463,109, which is approximately 13.696% of the company’s market cap and around 19.02% of the total institutional ownership; GILDER GAGNON HOWE & CO LLC, holding 3,109,874 shares of the stock with an approximate value of $25.34 million in PRVB stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $23.24 million in PRVB stock with ownership of nearly -32.486% of the company’s market capitalization.
Positions in Provention Bio Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 80 institutional holders increased their position in Provention Bio Inc. [NASDAQ:PRVB] by around 4,713,439 shares. Additionally, 40 investors decreased positions by around 3,522,584 shares, while 14 investors held positions by with 15,334,100 shares. The mentioned changes placed institutional holdings at 23,570,123 shares, according to the latest SEC report filing. PRVB stock had 28 new institutional investments in for a total of 1,077,906 shares, while 15 institutional investors sold positions of 914,094 shares during the same period.